Independent Lab Validates Powerful Collagen-Boosting and Antioxidant Efficacy of Revyntra Marine Active

BioMara
Sep 11
3 min read

Edinburgh, UK – 11 September 2025 – New In Vitro data from independent lab XCellR8 Ltd confirms that Revyntra, BioMara’s marine-derived fucoidan cosmetic ingredient, delivers industry-leading performance in collagen stimulation and antioxidant activity at low inclusion rates.

Launched earlier this year, Revyntra has already gained attention as a clean-beauty ingredient with an attractive sustainability story. Now, third-party efficacy testing has established a robust scientific foundation for Revyntra’s positioning as a hero ingredient in advanced skin care formulations.

Dr. Gill Westgate, Consultant and Director, Cosmetics Cluster UK says, “Actives such as Revyntra are arriving at exactly the right time for the cosmetics industry with the increasing adoption of ingredients from the Bioeconomy. With consumers demanding proven efficacy alongside sustainability and clean-beauty credentials, the market potential for this marine ingredient is significant across premium skin care, wellness and even ingestible beauty categories.”

Collagen Production: Outperforming Vitamin C at 10x Lower Dose

Using human dermal fibroblasts (HDFa) in a 2D cell model, the XCellR8 study measured soluble collagen released over a period of 48 hours of treatment with Revyntra.

Key results:

Up to 20x increase in collagen release vs untreated control
Significant boost from just 0.0075 mg/mL, with dose-dependent increases confirmed
Maximum collagen concentration of 611.65 µg/mL at 0.03 mg/mL Revyntra
Outperformed Vitamin C, which only showed a significant effect at a 10x higher dose (0.7 mg/mL) and with reduced cell viability

Revyntra achieved higher collagen output with better tolerability, making it highly attractive for sensitive skin and long-term formulations.

The lead cosmetic scientist at XCellR8, the lab responsible for the testing said “Our in vitro testing confirmed that Revyntra significantly increased soluble collagen release in human dermal fibroblasts at exceptionally low concentrations. The collagen-stimulating effect was dose-dependent, with Revyntra outperforming Vitamin C at an order of magnitude lower dose, while maintaining higher cell viability.”

Confirmed Inhibition of Key Skin-Aging Enzymes through complementary in-house testing

In complementary enzyme inhibition assays, Revyntra demonstrated:

100% inhibition of collagenase at 2% concentration under 60min
72% elastase inhibition at just 0.08% under 60min
Complete tyrosinase inhibition at 2% under 60min, supporting claims for pigmentation control induced by UV aging.

This confirms Revyntra’s multi-targeted mode of action in firmness, wrinkle reduction, and skin tone evenness, placing it alongside premium multifunctional actives in the anti-aging category.

Backed by Literature

Revyntra is backed by both third-party testing and a growing body of published research. In Vitro studies confirmed that fucoidan significantly inhibits UVB-induced enzymes responsible for collagen breakdown (Moon et al., 2008), reduces wrinkle depth with regular use at just 0.3% inclusion (Fitton et al., 2015), and acts as a potent superoxide radical scavenger (Achmad et al., 2024) – a key mechanism in reducing oxidative stress and slowing visible aging. Revyntra has passed OECD 492 and 439 safety protocols, confirming “non-irritant status” for eye and skin at concentrations up to 2%, making it suitable for sensitive skin applications.

Effective and Flexible Inclusion Rates

Revyntra delivers proven results at exceptionally low inclusion levels, offering formulators both efficacy and cost-efficiency. The minimum effective dose is 0.03%, with collagen-boosting effects measurable from just 0.0075 mg/mL for pre-clinical trials in 2D models. For premium claims, a hero dose of 0.1% and above is recommended. This versatility allows Revyntra to be used across a wide range of formats, from light serums and eye creams to overnight masks and nutricosmetics, without formulation challenges. In ingestible beauty formats, 10 mg per serving is the recommended starting dose for collagen and antioxidant support.

___

About BioMara

BioMara is a UK-based marine biotechnology company specialising in the extraction of high-purity, bioactive seaweed ingredients from sustainably ocean-farmed brown algae. Its proprietary extraction process is designed to preserve bioactivity while supporting zero-waste production and regional regenerative aquaculture supply chains.

BioMara sources its seaweed from regional regenerative farms and harvesters in the UK and EU. Seaweed cultivation requires no freshwater, arable land, or fertiliser inputs, and actively improves marine ecosystems. Working closely with local suppliers, BioMara enables a supply chain that supports coastal communities and contributes to a resilient blue bioeconomy.